Clinical trial
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine…
NCT00002224 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00002224 |
|---|---|
| Title | Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI) |
| Official title | Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Nelfinavir mesylate, Stavudine, Didanosine |
| Enrollment | 120 |
| Start date | Mar 1, 1999 |
| Primary completion | Mar 1, 1999 |
| Completion | Mar 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Apr 25, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: